Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Campos

Showing results (171-180 of 193) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Expert Opinion on Drug Safety|October 8, 2024
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Neurology|March 25, 2024
Predictive Model for Estimating the Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: The RISE ScoreDaniel Campos-Fernandez, Marc Rodrigo-Gisbert, Laura Abraira, et al.
Neurology|October 23, 2024
Author Response: Predictive Model for Estimating the Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: The RISE ScoreDaniel Campos-Fernandez, Laura Abraira, Manuel Quintana, et al.
International Journal of Obesity (2005)|December 7, 2018
Maternal prepregnancy body mass index and offspring white matter microstructure: results from three birth cohortsJuan Verdejo-Román, Lassi Björnholm, Ryan L Muetzel, et al.
Research Square|October 27, 2023
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Stroke|May 15, 2020
Computed Tomography Perfusion After Thrombectomy: An Immediate Surrogate Marker of Outcome After Recanalization in Acute StrokeMarta Rubiera, Alvaro Garcia-Tornel, Marta Olivé-Gadea, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in previously treated non-small-cell lung cancerFrances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, et al.
Genetic Testing and Molecular Biomarkers|May 20, 2020
Gene Copy Number Quantification of <i>SHOX</i>, <i>VAMP7</i>, and <i>SRY</i> for the Detection of Sex Chromosome Aneuploidies in NeonatesMarisol Ibarra-Ramírez, José de Jesús Lugo-Trampe, Luis Daniel Campos-Acevedo, et al.
Pageof 20

Showing results (171-180 of 193) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Expert Opinion on Drug Safety|October 8, 2024
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Neurology|March 25, 2024
Predictive Model for Estimating the Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: The RISE ScoreDaniel Campos-Fernandez, Marc Rodrigo-Gisbert, Laura Abraira, et al.
Neurology|October 23, 2024
Author Response: Predictive Model for Estimating the Risk of Epilepsy After Aneurysmal Subarachnoid Hemorrhage: The RISE ScoreDaniel Campos-Fernandez, Laura Abraira, Manuel Quintana, et al.
International Journal of Obesity (2005)|December 7, 2018
Maternal prepregnancy body mass index and offspring white matter microstructure: results from three birth cohortsJuan Verdejo-Román, Lassi Björnholm, Ryan L Muetzel, et al.
Research Square|October 27, 2023
Dapagliflozin cardiovascular effects on end-stage kidney disease (DARE-ESKD-2) trial: rationale and designJoaquim Barreto, Marilia Martins, Mauro Pascoa, et al.
Stroke|May 15, 2020
Computed Tomography Perfusion After Thrombectomy: An Immediate Surrogate Marker of Outcome After Recanalization in Acute StrokeMarta Rubiera, Alvaro Garcia-Tornel, Marta Olivé-Gadea, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in previously treated non-small-cell lung cancerFrances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, et al.
Genetic Testing and Molecular Biomarkers|May 20, 2020
Gene Copy Number Quantification of <i>SHOX</i>, <i>VAMP7</i>, and <i>SRY</i> for the Detection of Sex Chromosome Aneuploidies in NeonatesMarisol Ibarra-Ramírez, José de Jesús Lugo-Trampe, Luis Daniel Campos-Acevedo, et al.
Pageof 20